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Umbilical cord (UC) may represent an attractive cell source for allogeneic mesenchymal stem cell (MSC) therapy. The aim of this
in vitro study is to investigate the chondrogenic and osteogenic potential of UC-MSCs grown onto tridimensional scaﬀolds, to
identify a possible clinical relevance for an allogeneic use in cartilage and bone reconstructive surgery. Chondrogenic
diﬀerentiation on scaﬀolds was conﬁrmed at 4 weeks by the expression of sox-9 and type II collagen; low oxygen tension
improved the expression of these chondrogenic markers. A similar trend was observed in pellet culture in terms of matrix
(proteoglycan) production. Osteogenic diﬀerentiation on bone-graft-substitute was also conﬁrmed after 30 days of culture by
the expression of osteocalcin and RunX-2. Cells grown in the hypertrophic medium showed at 5 weeks safranin o-positive
stain and an increased CbFa1 expression, conﬁrming the ability of these cells to undergo hypertrophy. These results suggest
that the UC-MSCs isolated from minced umbilical cords may represent a valuable allogeneic cell population, which might have
a potential for orthopaedic tissue engineering such as the on-demand cell delivery using chondrogenic, osteogenic, and
endochondral scaﬀold. This study may have a clinical relevance as a future hypothetical option for allogeneic single-stage
cartilage repair and bone regeneration.
1. Introduction
Cartilage and bone lesions represent a common problem
in the orthopaedic practice, and tissue engineering is con-
stantly proposing innovative approaches to improve their
repair. Current treatments for cartilage defects are bone
marrow stimulation (microfractures), autologous osteochon-
dral transplantation, and autologous chondrocyte implanta-
tion. However, these options have speciﬁc limitations and
disadvantages: the poor quality of the repair tissue, the
donor-site morbidity, and the limited availability of tissue
[1]. For bone repair, the available bone substitutes are acellu-
lar and do not possess any osteogenic potential, representing
simple “gap-ﬁlling scaﬀold” to be populated by resident cells.
To overcome these issues, the use of autologous mesen-
chymal stem cells (MSCs) has gained popularity due to the
ability of these cells to diﬀerentiate toward chondrogenic or
osteogenic pathways. Generally, MSCs are derived from bone
marrow aspirations or from lipoaspirates, which contain an
undiﬀerentiated population of precursors, both CD34+ and
CD34− along with a great number of blood mononuclear
cells: These cell concentrates are currently used for one-
stage treatment of cartilage or bone defects [2–7]. The main
disadvantage of this approach is the limited number of MSCs
in the ﬁnal product [8]. Thus, the use of selected and precul-
tured MSCs is under investigation [9]. In this perspective,
allogeneic cells would eliminate the morbidity of harvesting
procedures and the costs linked to these procedures. Indeed,
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a cell factory may host a great number of selected allogeneic
stem cell lines from diﬀerent donors, readily available for
clinical use.
Besides the well-known sources as the bone marrow and
the fat, new allogeneic cell sources are emerging, such as the
umbilical cord stroma (UC) [8, 10–12]. The application of
cells derived from UC structure has some nonnegligible
advantages compared to other sources; these cells are indeed
isolated from a formerly discarded material that has a virtual
unlimited availability [12]. Moreover, UC contains two
umbilical arteries and one umbilical vein and a mucous
proteoglycan-rich connective tissue, named Wharton’s jelly,
covered by amniotic epithelium: Stem cells may be isolated
from each of these structures with a promising eﬃciency
[10, 13]. These cells have unique properties compared to
other stem cell types as they lie between embryonic stem cells
(ESCs) and adult mesenchymal stem cells (MSCs) on the
development map, they share stemness markers with ESCs
and MSCs, they do not induce tumorigenesis, and they are
hypoimmunogenic [14]. When taken together, the diﬀer-
ent UC-MSC subtypes constitute a “mixed” heterogeneous
MSC population, which is able to diﬀerentiate toward the
osteogenic, adipogenic, or chondrogenic lineage [15].
Thus, UC-MSCs may represent an appealing cell source
with a potential for clinical allogeneic use to treat chondral,
osteochondral lesions, and bone defects, being a possible
candidate for a “universal oﬀ-the-shelf” stem cell product in
the ﬁeld of orthopaedic tissue engineering [13].
The goal of this in vitro study was to evaluate the
capability of allogeneic UC-MSCs to diﬀerentiate toward
chondrogenic or osteogenic pathway in a tridimensional
environment and to test the possibility to address these cells
toward a hypertrophic stage, as a ﬁrst step to recapitulate the
endochondral ossiﬁcation.
2. Materials and Methods
Approvals were obtained both from the Ethical Committee
of MBC (Molecular Biotechnology Center), University of
Turin, and from the Ethical Committee of Mauriziano
Hospital, Turin (Italy); protocol number is CS792 approved
on January 11, 2016.
2.1. UC Collection and Processing. After obtaining patient’s
informed consent, 15 fresh UC samples were retrieved during
caesarean deliveries from the Department of Obstetrics and
Gynecology of Mauriziano Hospital (Turin, Italy). The UC
samples were collected in a phosphate-buﬀered saline (PBS)
transfer medium containing 200mg/100ml ciproﬂoxacin,
500 IU heparin, and they were immediately processed. After
transferring samples under a sterile laminar ﬂow cell culture
hood, the cord length and weight were estimated and the UC
was washed in PBS to remove traces of contaminant red
blood cells. The UC was ﬁrst cut into 3 cm long segments,
which were subsequently cut longitudinally and split open
to expose the inner surface.
The UC segments were then manually minced into small
cuboidal fragments (4–7mm length). The fragments were
seeded in 60 cm2 Petri dishes with the same expansion
medium in which they have been minced. This mesenchymal
stem cell expansion medium contained Dulbecco’s Modiﬁed
Eagle Medium/F-12 (DMEM) enriched with 5% human
platelet lysate obtained from healthy donors, 10% fetal
bovine serum (FBS), 1X penicillin/streptomycin, 1X sodium
pyruvate, 1X nonessential amino acids, 500 IU heparin
(Pharmatex). The small UC fragments were distributed into
6–7 diﬀerent 60 cm2 Petri dishes (approximately 40–45 frag-
ments/Petri dish) and incubated in the MSC expansion
medium at 37°C in a humidiﬁed atmosphere with 5% CO2
(day 0). Fragments of UC were left undisturbed in culture
and monitored for up to 2 weeks to allow identiﬁcation
of MSC in the dishes. Cell isolation was successful for 11
samples out of 15.
2.2. UC-MSC Culture. After 2 weeks (day 14), the UC
debris were removed and adherent cells were expanded
for 2 additional weeks; cell expansion was reached for 11
samples out of 15. Forty percent of the medium was changed
every 3–4 days. After 2 weeks, the adherent cells (P0) were
trypsinized, centrifuged at 1200 rpm for 10min, resuspended
in the MSC expansion medium, and replated for one consec-
utive expansion step at a density of 100–200 cells/cm2, until
full conﬂuence was reached (P1). Cell conﬂuence at P1 was
reached after approximately 14 days (day 42). At the end of
P1 passage (day 42), living cells were counted by trypan blue
dye exclusion.
2.3. Telomere Length Analysis. Telomere length was evalu-
ated on UC-MSCs at P1 from 4 UCs, and results were com-
pared to telomere length of the same cell line at sequential
passages from P2 to P5, following a previously reported
method [15].
2.4. UC-MSC Immunophenotypic Characterization. Immu-
nophenotyping of the expanded UC-MSCs was done by
ﬂow cytometry analysis at P1. 1,5× 106 UC-MSCs were
used for ﬂow cytometry. The following antibodies were
used: CD90-peridinin chlorophyll protein- (PerCP-) cyanine
dye Cy5.5 (Biolegend, San Diego, CA), CD105-ﬂuorescein
isothiocyanate (FITC) (Biolegend, San Diego, CA), CD73-
allophycocyanin (APC) (BD Biosciences, San Jose, CA),
CD34-phycoerythrin (PE) (BD Biosciences, San Jose, CA),
HLA-DR-FITC (BD Biosciences, San Jose, CA), HLA-
PerCP (BD Biosciences, San Jose, CA), HLA-ABC-PE,
CD29-APC (BD Biosciences, San Jose, CA), CD44-Alexa
Fluor (Cell Signaling Technology, Danvers, MA), PE-
conjugated antimouse immunoglobulin G (IgG) (Southern
Biotechnology Associates, Birmingham, Alabama, USA),
isotype-matched IgG-FITC (Biolegend, San Diego, CA),
IgG-PE (Biolegend, San Diego, CA), and IgG-PE-Cy5
(Biolegend, San Diego, CA) control antibodies. Analysis
was performed on a FACScan (Becton Dickinson (BD),
Buccinasco, Italy) for at least 10.000 events and using
CellQuest software (BD, Buccinasco, Italy).
2.5. Section 1: UC-MSC Diﬀerentiation on Chondrogenic
Scaﬀold. UC-MSCs at P1 were assessed for chondrogenic dif-
ferentiation on scaﬀolds. UC-MSCs were loaded onto two
diﬀerent scaﬀolds: Hyaﬀ-11 (FIDIA Advanced Biopolymers,
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Italy) or Chondro-gide (Geistlich Biomaterials, Italy S.r.l.)
membranes. Hyaﬀ-11 is a nonwoven esteriﬁed HA derivative
membrane. Chondro-gide is a double-layer matrix of pig
collagen type I and type III, with a smooth compact side
and a porous side, where cells are seeded. After the ﬁrst
passage of cell culture, 2× 106 UC-MSCs were resuspended
in 50μl of the chondrogenic diﬀerentiation medium and
seeded onto a scaﬀold surface of 1 cm2 (either Hyaﬀ-11 or
Chondro-gide). The scaﬀolds were left at 37°C in a
humidiﬁed atmosphere with 5% CO2 for 3–4 hours to allow
UC-MSC adhesion on the scaﬀolds. Then, two drops of
commercial ﬁbrin glue (Tissucol-Tisseel, Baxter) were added
as a surface sealing, and the ﬁnal constructs were incubated
at 37°C, in a humidiﬁed atmosphere for 1 month in the
presence of the chondrogenic diﬀerentiation medium
(EUROMED Chondrogenic Diﬀerentiation Kit, EuroClone,
Pavia, Italy). Cultures were performed both in normoxic
conditions (21% O2) or at low oxygen tension (8% O2).
After 1 month, constructs were ﬁxed in formalin,
included in paraﬃn, and sectioned. Sections were stained
for haematoxylin/eosin and examined under light micros-
copy. For cell counting, three diﬀerent areas in two diﬀerent
sections per construct were examined under light microscopy
at 20x magniﬁcation by two independent observers. Cell
number for each single area was deﬁned by the arithmetical
mean of the cell counts from both observers. Mean numbers
of migrating cells from every area were statistically compared
and graphed with GraphPad Prism®. Safranin o staining
was also performed on sections.
Expression of chondrocyte markers, sox-9 (AB5535,
Merck Millipore, Milano, Italy), and collagen type II (clone
6B3, MAB8887, Merck Millipore, Milano, Italy) was assessed
using immunoﬂuorescence techniques. The primary mono-
clonal antibodies were diluted in PBS-BSA1% and incubated
with the sections for 2 h at room temperature. The secondary
dye light 488 antibody (KPL, Kirkegaard & Perry Labora-
tories, Maryland, USA), diluted 1 : 100, was incubated for
1 h at room temperature. The stained sections were visual-
ized with an Apotome ﬂuorescence microscope. We col-
lected digital images using a ×20 dry lens within 0–5 days
after labelling.
The same culture conditions were used for UC-MSC
pellet culture. Proteoglycan (PG) :DNA ratio was calculated
as the best approximation of ECM production per cell follow-
ing a previously reported method [16].
2.6. Section 2: UC-MSC Diﬀerentiation in Osteogenic Scaﬀold.
For osteogenic diﬀerentiation on scaﬀold, we used the
Orthoss® bone graft (Geistlich Biomaterials, Italy S.r.l.), a
bovine-derived natural commercial bone substitute. Its
inorganic bone matrix has a macro- and microporous struc-
ture similar to human cancellous bone. Scaﬀolds were cut
into cubes of approximately 1 cm3. The cubes were then
coated with ﬁbronectin by soaking in a solution containing
50mg/ml ﬁbronectin for 4 h at room temperature. The cubes
were air dried overnight in a sterile bio safety cabinet. The
cubes were seeded with UC-MSCs resuspended in ﬁbrin glue
(6× 106 cells/scaﬀold). Then the osteogenic diﬀerentiation
medium was added (EUROMED Osteogenic Diﬀerentiation
Kit, EuroClone, Pavia, Italy), and constructs were incubated
at 37°C in a humidiﬁed atmosphere with 5% CO2 for 10,
20, and 30 days.
At the end of culture, constructs were initially decalci-
ﬁed and then ﬁxed in formalin, included in paraﬃn, and
sectioned. Sections were stained for haematoxylin/eosin
and Alizarin red and examined under light microscopy.
Expression of osteocalcin ([Tyr28-, Phe42-, and Phe46-]
bone Gla protein, Phoenix Pharmaceuticals Inc., Burlingame,
CA, USA) and core-binding factor subunit alpha-1/runt-
related transcription factor 2 Cbfa1/RunX-2 (Ab 114,133,
Abcam, Cambridge, MA, USA) markers was assessed using
immunoﬂuorescence techniques described above. The stained
sections were visualized with an Apotome ﬂuorescence micro-
scope. We collected digital images using a× 20 dry lens
within 0–5 days after labelling.
2.7. Section 3: UC-MSC Hypertrophic Diﬀerentiation. To
verify the UC-MSC potential for endochondral diﬀerentia-
tion, cells at P2 were seeded onto Orthoss 3 g granules of
approximately 4mm3 of volume (concentration: 25× 104
cells/granule) and incubated at 37°C in a humidiﬁed atmo-
sphere with 5% CO2, in three diﬀerent conditions:
(i) Hypertrophic culture (3 weeks + 2 weeks)
(1) Chondrogenic medium (Chondrogenic Diﬀer-
entiation Kit, EuroClone), for 3 weeks
(2) Hypertrophic medium (DMEM, 10mM Hepes
Buﬀer, 1mM Na pyruvate, 1% penicillin/strep-
tomycin/glutamine, 1% ITS-A, 4.7μg/ml lino-
leic acid, 1.25mg/ml human serum albumin,
0.1mM ascorbic acid 2-phosphate, 10−8M
dexamethasone, 10mM β-glycerophosphate,
0.05μM L-thyroxin) for the following 2 weeks
This peculiar condition was compared with two
other culture conditions:
(ii) Osteogenic culture (αMEM, 10% fetal calf serum,
0.1mM ascorbic acid 2-phosphate, 10−8M dexa-
methasone, 10mM β-glycerophosphate) for 3 and
5 weeks
(iii) Basal (control) culture: DMEM +10% fetal calf
serum, 50U/ml penicillin/streptomycin for 3 and
5 weeks
At the end of culture (3 and 5 weeks), H&E and safranin
o staining were performed, following the manufacturer’s
protocols (Bio-Optica Milano SpA, Milan, Italy). Further-
more, real-time PCR analysis was completed to analyze gene
expression of the major chondrogenic and osteogenic
markers (sox-9, Cbfa1).
2.7.1. RT-PCR Analyses. Total RNA was extracted from
constructs using TRIzol® (Life Technologies), and cDNA
was generated as previously described [17]. The PCR master
mix was based on AmpliTaq Gold DNA polymerase (Perkin
Elmer/Applied Biosystems). TaqMan® gene expression or on-
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demand assays (Life Technologies) were used on a ABI 7900
fat real-time PCR system (Life Technologies) for 40 cycles to
measure gene expression of sox-9 (Hs00165814_m1) and
Cbfa1 (Hs00231692_m1) using GAPDH (Hs99999905_m1)
as the housekeeping gene.
2.8. Evaluation of Fluorescence Intensity. The diﬀerence of
ﬂuorescence intensity between the constructs was evaluated
using ImageJ program. This software generated numerical
semiquantitative evaluations corresponding to the mean
ﬂuorescence intensity of each image examined. Ten cellular
ﬁelds were randomly chosen among the diﬀerent areas of
migrated chondrocytes in each slide. Brieﬂy, a point tool
enables the marking of locations on an image. With each
“click,” the coordinates of the mark (xx, yy) and brightness
values (0–255) are recorded in a data window. ImageJ bright-
ness units are in a scale where 0=pure black and 255=pure
white. Brightness values for each image were calculated as
the arithmetical mean of all values in all ﬁelds recorded for
that image. For each construct, mean ﬂuorescence intensity
of each marker was calculated and plotted as a graph. The
diﬀerence in intensity allowed for evaluating the change in
marker expression between the diﬀerent culture conditions.
2.9. Statistical Analysis. All data in text and ﬁgures are
provided as medians. Statistical analysis was carried out with
the statistical software package GraphPad Prism 5.0. The
results are shown as box plots, where the transverse line rep-
resents the median value, and the width of the box is given by
the minimum and the maximum value of the data. If only
two conditions are compared, we used Mann–Whitney test
and we did not assume Gaussian distribution; if more than
two conditions are compared, we used one-way ANOVA
and Bonferroni adjustment.
3. Results
3.1. UC-MSC Morphologic and Immunophenotypic
Characterization. In primary cultures, typical spindle-
shaped adherent cells were observed migrating from the
UC tissue fragments and initiating colony formation
approximately at day 14 after seeding. After removing
the UC fragments at day 14 postseeding, cells took approxi-
mately 10 days to gain 60% conﬂuence (Figure 1(a)), while
full conﬂuence was observed approximately at day 28
postseeding. The UC-MSC clones (deﬁned as passage P0)
were thus collected at day 28 postseeding and replated for
further expansion (deﬁned as passage P1). Conﬂuence at
P1 was observed approximately after 14 days of culture
(day 42 postseeding).
At day 42 (conﬂuence at P1 passage), we obtained a mean
of 23.05× 106 (SD 1.48) cells from each umbilical cord. From
the initial seeding (day 0), we obtained at the end of the
P1 (day 42) 0.80× 106 (SD 0.28) cells/g of UC seeded
(mean weight of the UC 30.65 g − mean length 40.9 cm)
(Supplemental Figure 1 available online at https://doi.org/
10.1155/2017/1732094). UC cells’ phenotype was analyzed
by ﬂow cytometry. The majority of collected UC cells
showed a positive expression of the main MSC markers
CD73, CD90, and CD105, as well as of CD44 and CD29.
Furthermore, they stained negative for the typical hemato-
poietic marker CD34 (Supplemental Figure 2). The data
also demonstrated the presence of HLA-ABC proteins
and the absence of HLA-DR. Additionally, we visualized
a notable presence (40%) of negative double cells for both
HLA-ABC and HLA-DR proteins.
Telomere length analysis performed on UC-MSCs at
diﬀerent culture passages (from P1 to P5) did not show any
signiﬁcant diﬀerence (Figure 1(b)).
3.2. Section 1: Chondrogenic Diﬀerentiation in Scaﬀold.
During chondrogenic diﬀerentiation onto Chondro-gide
and Hyaﬀ-11 scaﬀolds, cells showed chondrogenic commit-
ment both in normoxic conditions and in low oxygen
tension, albeit UC-MSCs cultured at lower oxygen tension
showed more positive safranin o staining, consistent with
increased sulfated glycosaminoglycan (s-GAG) production
(Figure 2(a), C and D). Furthermore, histological analysis
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Figure 1: UC-MSC morphological characterization. (a) UC-MSCs at P1. Cells show a ﬁbroblast-like morphology. Magniﬁcation 10x.
(b) UC-MSC telomere length analysis at diﬀerent passages (between P1 and P5); no diﬀerence is detected; n of samples = 4.
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showed that MSCs migrated inside the tridimensional struc-
ture of the Hyaﬀ-11 scaﬀold, while they remained almost
complete at the porous surface on the Chondro-gide mem-
brane (Figure 2(a), A and B), probably due to the diﬀerent
composition of the scaﬀolds. No signiﬁcant diﬀerence in
the number of cells per ﬁeld was observed between normoxic
cultures and low oxygen tension conditions for each speciﬁc
scaﬀold (Figure 2(b)).
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Figure 2: Chondrogenic diﬀerentiation of UC-MSCs seeded on a scaﬀold. (a) A representative image of safranin o staining of UC-MSCs
seeded onto Chondro-gide (A and B) or Hyaﬀ (C and D) membranes and cultured in normoxic (A and C) or low oxygen tension
conditions (B and D). UC-MSCs diﬀerentiate inside the three-dimensional structure of the HYAFF-11, while they are conﬁned to the
surface of the Chondro-gide scaﬀold. A stronger safranin o staining is observed in the low oxygen tension constructs than in normoxic
culture. Magniﬁcation 20x. Scale bar: 200μm in (A and B); 100μm in (C and D). (b) No signiﬁcant diﬀerence in cell number per
ﬁeld is observed comparing normoxic and in low oxygen tension conditions in Chondro-gide (A) (median value and standard deviation:
174± 32.07; 157.5± 40.32 for low oxygen tension and normoxia, resp.) and Hyaﬀ (B) (median value and standard deviation: 82.50± 24.96;
110± 6952 for low oxygen tension and normoxia, resp.) scaﬀolds. p value> 0.05; n of samples = 3.
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In Chondro-gide scaﬀolds, positive immunostaining for
sox-9 was present both in normoxic culture and at low
oxygen tension conditions (Figure 3(a), A and B). A sig-
niﬁcantly higher ﬂuorescence intensity was observed in
constructs cultured art low oxygen tension (p value < 0.05)
(Figure 3(a), C). Collagen type II expression in Chondro-
gide scaﬀold was present both in low oxygen tension and
under normoxic conditions (Figure 3(b), A and B); how-
ever, ﬂuorescence intensity was not signiﬁcantly diﬀerent
(p value = 0.6926) (Figure 3(b), C). Negative controls are
shown in Supplemental Figure 3.
In Hyaﬀ-11 scaﬀolds, we noticed a similar trend:
Positive immunostaining for sox-9 was noticed both at low
oxygen tension and in normoxic cell cultures (Figure 4(a),
A and B). The diﬀerence in ﬂuorescence intensity
resulted statistically signiﬁcant (p value< 0.05) (Figure 3(a),
C). Collagen type II expression in Hyaﬀ-11 scaﬀolds was
signiﬁcantly greater at low oxygen tension (p value< 0.05)
(Figure 4(b), C). Negative controls are shown in Supple-
mental Figure 4.
A similar trend was observed in UC-MSC pellet cultures
when exposed to low oxygen tension during culture period.
We observed a stronger safranin o staining (Figures 5(a)
and 5(b)) and higher PG/DNA ratio (Figure 5(c)) in pellet
culture grown at low oxygen tension compared to those
exposed to normoxic conditions (p value< 0.05).
3.3. Section 2: Osteogenic Diﬀerentiation in Bone Substitutes.
Scaﬀolds showed a considerable increasing cellularity in
constructs at diﬀerent time points (10, 20, and 30 days)
(Figure 6(a)). Alizarin red stain showed calcium deposits
gradually increasing from 10, 20, to 30 days (Figure 6(b)).
Semiquantitative analysis of osteocalcin immunostaining
(Figure 7(a), A–C) showed a signiﬁcant increased intensity
of osteocalcin expression between 20 days and 30 days;
for the other time points, there was an increased expres-
sion, though it did not reach a signiﬁcant diﬀerence
(Figure 7(a), D; p value< 0.05). Similar results were obtained
for the expression of the transcriptional factor RunX-2,
(Figure 7(b), A–C) which is a key transcription factor
associated with osteoblast diﬀerentiation (Figure 7(b), D)
(p value< 0.05). Negative controls are shown in Supple-
mental Figure 5.
3.4. Section 3: Endochondral Diﬀerentiation in Bone
Substitute Granules. At 3 weeks of culture, deposition of a
cartilaginous matrix was observed in the samples cultured
with the chondrogenic induction medium, while there was
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Figure 3: Chondrogenic diﬀerentiation of UC-MSCs seeded on Chondro-gide. (a) A representative image of immunoﬂuorescence staining
for sox-9 in Chondro-gide scaﬀold at low oxygen tension (A) and normoxic (B) conditions. Quantiﬁcation of the signal is shown in (C):
Fluorescence intensity is signiﬁcantly higher in constructs grown at low oxygen tension (median value and standard deviation: 20± 6122;
11± 2102 for low oxygen tension and normoxia, resp.). p value< 0.05. Magniﬁcation 20x; n of samples = 3. (b) A representative image of
immunoﬂuorescence staining for collagen type II in Chondro-gide scaﬀold at low oxygen tension (A) and normoxic (B) conditions. Signal
quantiﬁcation is shown in (C); no signiﬁcant diﬀerence in ﬂuorescence intensity is observed (median value and standard deviation:
17± 3279; 17± 4025 for low oxygen tension and normoxia, resp.). p value = 0.6926. Magniﬁcation 20x; n of samples = 3.
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no evidence of osteogenic diﬀerentiation in speciﬁc diﬀeren-
tiation medium (Figure 8(a)). At 5 weeks of culture, we
observed a stronger safranin o staining in samples cultured
in the chondrogenic hypertrophic medium, as well as the
production of bone matrix in samples cultured in the osteo-
genic diﬀerentiation medium (Figure 8(b)).
Real-time PCR analysis showed a mild upregulation of
sox-9 expression in samples cultured for 3 weeks in the chon-
drogenic medium. Also, the osteogenic marker Cfba-1 was
upregulated in samples cultured both in chondrogenic and
in the osteogenic medium. After 5 weeks of culture, sox-9
expression was downregulated in samples cultured with the
chondrogenic hypertrophic medium, whereas Cfba-1 was
upregulated. The osteogenic medium induced a strong
Cfba-1 upregulation (Figure 9).
4. Discussion
The main ﬁnding of this study is that UC-MSCs collected in a
straightforward and simple procedure from minced umbili-
cal cord fragments may be committed toward chondrogenic
and osteogenic lineages, when cultured in scaﬀolds, and they
may also be addressed toward hypertrophy when cultured in
bone substitute in the presence of the chondrogenic and
hypertrophic chondrogenic medium. Thus, UC-MCs may
represent an allogeneic cell population with a promising
value for on-demand cell delivery in single-stage cartilage
repair and bone regeneration.
Nowadays, the use of allogeneic cells for cartilage and
bone repair is an ongoing frontier due to the increasing need
of cells for better speciﬁc tissue repair.
Indeed, the simple use of bone marrow stimulating tech-
niques, such as microfracture, has shown some limitations
linked to the restricted durability of the repair and the lesser
quality of the tissue obtained, compared to that achieved by
more complex reconstructive techniques as autologous
chondrocyte implantation [18–20] or scaﬀold-driven repair
enriched by autologous bone marrow MSCs [21]. Even
the use of bone substitutes has shown lesser results when
compared with techniques combining bone substitute with
biological stimuli as autologous bone marrow MSCs or
autologous stem cell mobilization through growth factors
as G-CSF (granulocyte colony stimulating factor) [22, 23].
However, the use of an autologous cell source has several
disadvantages mainly due to the morbidity of the harvest-
ing procedure, the individual variability in the cell
number, and the limited number of cells available by each
harvesting procedure. Moreover, the use of selected
precursor cells (i.e., precultured autologous stem cells,
chondrocytes) is necessarily associated with multiple
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Figure 4: Chondrogenic diﬀerentiation of UC-MSCs seeded on Hyaﬀ. (a) A representative image of immunoﬂuorescence staining for sox-9
in Hyaﬀ scaﬀold at low oxygen tension (A) and normoxic (B) conditions. Quantiﬁcation of the signal is shown in (C): Fluorescence intensity is
signiﬁcantly higher in constructs grown at low oxygen tension (median value and standard deviation: 18± 5194; 13± 1917 for low oxygen
tension and normoxia, resp.). p value< 0.05. Magniﬁcation 20x; n of samples = 3. (b) A representative image of immunoﬂuorescence
staining for collagen type II in Hyaﬀ scaﬀold at low oxygen tension (A) and normoxic (B) conditions. Signal quantiﬁcation is shown in
(C): Fluorescence intensity is signiﬁcantly higher in constructs grown at low oxygen tension (median value and standard deviation:
9± 2601; 6± 1594 for low oxygen tension and normoxia, resp.). p value< 0.05. Magniﬁcation 20x; n of samples = 3.
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Figure 5: UC-MSC chondrogenic diﬀerentiation in pellet culture. A representative image of safranin o staining of UC-MSCs in pellet culture
(a and b). Stronger safranin o staining is observed in UC-MSC pellets cultured at low oxygen tension (a) when compared to normoxic
conditions (b). Higher PG/DNA ratio in pellets cultured at low oxygen tension is shown in (c) (median value and standard deviation:
0.05166± 0.02240; 0.07468± 0.01687 for and normoxia and low oxygen tension, resp.). p value< 0.05. Magniﬁcation 20x. Scale bar:
200 μm. n of samples = 3.
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Figure 6: UC-MSC osteogenic diﬀerentiation on the Orthoss scaﬀold. (a) A representative image of H&E staining of UC-MSCs loaded onto
Orthoss scaﬀold at 10 (A), 20 (B), and 30 (C) days of in vitro culture. Magniﬁcation 20x. Scale bar: 200 μm. (b) A representative image of
Alizarin red staining of UC-MSCs loaded onto Orthoss scaﬀold at 10 (A), 20 (B), and 30 (C) days of in vitro culture. Magniﬁcation 20x.
Scale bar: 100 μm.
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procedures to obtain the primary autologous source, to
culture the cells and to reimplant the cells at the lesion
site. An ongoing solution proposed in literature is the “one-
step procedures” in which autologous unselected sources
of cells, as bone marrow concentrate [24], cartilage frag-
ments [1, 25], or stromal vascular fraction from lipoaspi-
rates [5] are added at the lesion site (cartilage or bone
defect) obtaining interesting results, even if in these
instances, a noncommitted cell population is used to
enhance the repair.
In line with the concept of “one-step procedure,” the
evolving technologies in cell storage and cell culture allow
for hypothesizing the use of allogeneic cells as an attractive
choice for cartilage and bone repair, due to the greater bio-
availability of allogeneic sources compared to the autologous
ones. Thus, the concept of allogeneic stem cell therapy is
becoming an ongoing reality. Indeed, in several clinical ﬁelds,
such as neurology, gastroenterology, or hematology, these
principles are used in experimental studies to treat diﬀerent
diseases like cerebral palsy [26], autoimmune encephalomy-
elitis [27], perianal ﬁstulas in Crohn’s disease [28], liver
failure [29], and aplastic anemia [30]. The main advantages
in the use of allogeneic cells in orthopedics are a greater
“on-demand” availability of cell precursors, the absence of
harvesting morbidity, the possibility to obtain a selected cell
population, and even the possibility to use cells from younger
donors for lesions in older recipient, further optimizing the
quality of the repair. The latest aspect has recently found a
preclinical application in the study of Bonasia et al. [1], in
which allogeneic juvenile cartilage fragments have been used
to improve the quality of cartilage repair in a rabbit model
obtaining positive results. This work suggests the possibility
to use juvenile fresh allogeneic tissue grafts as a source for
the repair. This concept is certainly an option for bone and
cartilage reconstruction, but it implies several drawbacks as
the prompt bioavailability of the speciﬁc tissues and the costs
of tissue preservation, posing some concerns about a wide-
spread application of these principles.
A diﬀerent solution is to use allogeneic candidates from
diﬀerent anatomical sites as bone marrow and adipose tissue.
In the in vivo study by de Windt et al. [31], cartilage defects
are treated by combining allogeneic bone marrowMSCs with
autologous chondrons obtained by digesting minced carti-
lage fragments. Result of this phase I study seems promising,
though in that case, the length of the entire procedure (i.e.,
obtaining autologous chondrons + combination of the 2
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Figure 7: Expression of osteogenic markers in UC-MSCs seeded onto Orthoss cubes. (a) A representative image of immunoﬂuorescence
staining for osteocalcin in Orthoss at 10 (A), 20 (B), and 30 (C) days of in vitro culture. Quantiﬁcation of the signal is shown in (D):
Fluorescence intensity is signiﬁcantly higher in samples cultured for 30 days (median value and standard deviation: 9604± 0.2584;
10.85± 0.3990; 13± 1030 in samples cultured for 10, 20, or 30 days, resp.). p value< 0.05. Magniﬁcation 20x; n of samples = 5. (b) A
representative image of immunoﬂuorescence staining for RunX-2 in Orthoss at 10 (A), 20 (B), and 30 (C) days of in vitro culture.
Quantiﬁcation of the signal is shown in (D): Fluorescence intensity signiﬁcantly increases in the longer experimental time points (median
value and standard deviation: 7± 1340; 11± 1712; 18± 3090 in samples cultured for 10, 20, or 30 days, resp.). p value< 0.05. Magniﬁcation
20x; n of samples = 5.
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sources of repair + surgical implantation) may represent a
drawback, if compared to more “straightforward” procedures
in which a cellularized scaﬀold is directly implanted at the
lesion site. In preclinical rabbit and minipig models, alloge-
neic bone marrow-derived MSC implantation has been
proposed for the treatment of knee osteochondral defects
with promising results [32, 33]. Bone regeneration has been
obtained in a study by Kang et al. [34] loading allogeneic
bone marrowMSCs onto allogeneic cancellous bone granules
in a rabbit radial defect model, with a quality of repair
comparable to that with autologous BM-MSCs. In several
preclinical studies, allogeneic adipose-derived MSCs (ASCs)
have also improved bone and cartilage repair. In the study
conducted byWen et al. [35], ASCs have been combined with
demineralized bone matrix (DBM) have been applied in
ulnar bone defects in rats with promising results. Even the
intra-articular injection of allogeneic, ASCs have led to
satisfying outcomes when combined with hyaluronic acid
(A) (B) (C)
(D) (E) (F)
(a)
(A) (B) (C)
(D) (E) (F)
(b)
Figure 8: Hypertrophic diﬀerentiation of UC-MSCs seeded onto Orthoss granules. (a) A representative image of safranin o and H&E staining
of UC-MSCs seeded onto Orthoss granules and cultured for 3 weeks in the hypertrophic medium (Safranin O stain, A and D), osteogenic
medium (H&E stain, B and E) or basal medium (H&E stain, C and F), respectively. Scale bar: 100μm; n of samples = 5. (b) A
representative image of safranin o and H&E staining of UC-MSCs seeded onto Orthoss granules and cultured for 5 weeks in the
hypertrophic medium (Safranin O stain, A and D), osteogenic medium (H&E stain, B and E), or basal medium (H&E stain, C and F),
respectively. Scale bar: 100μm; n of samples = 5.
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in preclinical models of dog arthropathy [36, 37] and sheep
osteoarthritis [38].
The umbilical cord-derived MSCs (UC-MSCs) may
represent a novel interesting alternative in this ﬁeld [39].
The umbilical cord is considered a discarded material, and
its use implies fewer ethical and legal issues than the other
embryonic structures (i.e., embryonic stem cells). Further-
more, it has a virtually “unlimited availability,” as recently
deﬁned by Kalaszczynska and Ferdyn [8]. Moreover, the
low costs and the absence of morbidity related to the collect-
ing procedure are a “nonnegligible” advantage compared to
the other common allogeneic cell sources, such as bone
marrow and adipose tissue.
In literature, UC-MSCs have shown a favorable in vitro
potential as they can diﬀerentiate toward both the chondro-
genic and the osteogenic lineage similarly to the bone
marrow MSCs [40, 41]. Indeed, like the bone marrow coun-
terpart, UC-MSCs react to low oxygen tension conditions
[42] or to pulsed electromagnetic ﬁelds [43] showing an
improved chondrogenic commitment. The promising
multidiﬀerentiation potential may be due to the peculiar site
of origin leading to a “more embryonic” feature than the
bone marrow counterpart [14, 44, 45]. Indeed, they have
been recently used in vivo as described by Sadlik et al. [46]
involving the dry arthroscopic treatment of cartilage lesions
with UC-MSCs embedded in a porcine type I/II collagen
matrix. Dilogo et al. [47] also used UC-MSCs for the
treatment of a critical-sized bone defect; however, literature
suggests caution before a widespread clinical application,
claiming for a better understanding of the functional charac-
teristics of these cells [10]. Nonetheless, a recent evidence has
added a further promising opportunity in the ﬁeld of UC-
MSCs. In recent studies, Mennan et al. [48] and Hendijani
et al. [49] have demonstrated that a mixed cell population
obtained by processing the whole umbilical cord seems to
have the same diﬀerentiation potential than cells derived
from single areas of the cord (Wharton’s jelly, artery, vein,
or cord lining). These ﬁndings might suggest the possibility
to obtain optimal precursor cells without any concern about
the separation of speciﬁc population, simplifying any theo-
retical use of the cord as a source of cells for future hypothet-
ical widespread clinical application.
In line with these perspectives, our study has analyzed the
in vitro chondrogenic and osteogenic commitment of a
mixed UC-MSC population, obtained with a very simple
and economic protocol without any enzymatic digestion.
No cell selection has been performed during the MSC extrac-
tion from cord stroma, but the adherent properties of UC-
MSCs and the simple mincing of the cord fragments
represented the essential steps of our cell isolation method.
This choice is in line with the aforementioned evidences in
literature [48, 49], and it allows for greatly simplifying the cell
harvesting without reducing the eﬃciency of the protocol, as
recently outlined by Yoon et al. [50].
Both human platelet lysate obtained from healthy
donors and fetal bovine serum (FBS) were used for cul-
ture, as described in a previously published paper [15],
in order to optimize the broth conditions for the cells.
For a human hypothetical application, the FBS may arise
ethical concerns [51]. Thus, the choice of using human
platelet lysate only seems to be preferable for future human
trials. Further study might compare the eﬃcacy of this
method with and without FBS to ensure that an adequate
number of cells may be obtained in both conditions.
Indeed, our protocol led to a consistent number of
cells per gram of tissue, thus suggesting a possible future
large-scale nonexpensive cell storage for clinical purposes,
as Kalaszczynska and Ferdyn envisioned in a recent
review [8].
UC-MSCs obtained with our method have shown
stemness properties in terms of markers and telomere preser-
vation, the latter suggesting a maintenance of cell viability, as
recently outlined in literature [8]. Moreover, UC-MSCs
showed a low expression of HLA-I and no expression of
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Figure 9: Expression of osteogenic markers in UC-MSCs undergoing hypertrophy. Quantiﬁcation of sox-9 (a) and Cfba-1 (b) gene
expression by RT-PCR analysis at 3 or 5 weeks of culture in the three experimental groups. GAPDH used as gene of reference; n of
samples = 5.
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HLA-II, consistent with a possible safe allogeneic use. This
concept is conﬁrmed by a recent study by Liu et al. [44] in
which the authors demonstrated that the immunoprivileged
status of UC-MSCs seems to be maintained even during
the diﬀerentiation process toward a speciﬁc mesenchymal
(i.e., chondrogenic) lineage. Furthermore, the ﬁnding of
an “HLA-I and HLA-II double negative” cell subpopulation
suggests peculiar immunoprivileged properties of these cells
that may deserve future studies to verify the possible isolation
of this cellular subtype, their speciﬁc diﬀerentiation poten-
tials, and their hypothetical elective use as preferential
candidate for allogeneic therapies.
To test UC-MSC chondrogenic commitment in a tridi-
mensional environment, two widely used scaﬀolds have been
compared (Chondro-gide and Hyaﬀ). We have observed cell
growth on both membranes, with diﬀerences in cell distribu-
tion depending on the tridimensional scaﬀold structures.
Nevertheless, in both experimental groups, cells showed a
chondrogenic phenotype and they stained positive for the
chondrogenic markers sox-9 and collagen type II. Notably,
the low oxygen tension exerted an inﬂuence on UC-MSCs,
similar to bone marrow-derived MSCs [52]. Speciﬁcally,
low oxygen tension did not hamper UC-MSC proliferation
potential, but it led to an increased matrix production in
UC-MSC pellet cultures and to an enhanced chondrogenic
marker expression in UC-MSC scaﬀold cultures, consistent
with previous studies [42]. This increased chondrogenic dif-
ferentiation might be the result of hypoxia-inducible factor-1
alpha and factor-2 alpha stabilization and the subsequent
sox-9 induction [53–56]. Further in vitro analyses are
necessary to better clarify this speciﬁc aspect. Overall, a clear
chondrogenic commitment has been observed with both
scaﬀolds, with a slight greater evidence of collagen II produc-
tion when UC-MSCs were grown on a hyaluronic acid
membrane. This is consistent with several evidences in
literature that showed a possible and eﬃcient chondrogenic
diﬀerentiation of mesenchymal stem cells derived from
Wharton’s jelly in diﬀerent conditions, as the high-density
cell cultures on rotatory systems [57], the culture in collagen
hydrogels [58], or the cell growth on polycaprolactone/
collagen nanoscaﬀolds [40].
Like the chondrogenic diﬀerentiation, the osteogenic
commitment was obtained using a commercial organic bone
substitute used for clinical applications, to closely mimic the
clinical application. Indeed, the common bovine-derived
bone matrix used in this study is widely accepted in clinical
scenarios as gap ﬁlling in the presence of bone defects. We
have observed an osteogenic potential similar to other studies
where cells from umbilical cord were grown in monolayer
[15] or in tridimensional scaﬀold as collagen I/III gels [59]
or even when loaded onto bone scaﬀold and subcutaneously
implanted in nude mice [60]. Our results, along with the
available literature, suggest that UC-MSCs might represent
a possible source allogeneic cells for bone tissue engineering.
These observations are further conﬁrmed by the last sec-
tion of our experiments. The idea of these experiments has
been inspired by Scotti et al. [61], who conceived a complex
preclinical model to demonstrate the feasibility of engineer-
ing a functional bone organ by preconditioning bone
marrow-derived MSCs, embedded in type I collagen meshes,
toward hypertrophic chondrocytic phenotype and subse-
quently implanting the scaﬀolds in the dorsal subcutaneous
tissue of nude mice. The dramatic originality of Scotti’s study
and the potential for bone engineering are unquestionable.
Indeed, bone repair mainly occurs through endochondral
ossiﬁcation and the possibility to recapitulate this process
may allow for conceiving a “second generation” cell-seeded
bone substitutes with increased eﬃciency to strongly facili-
tate bone repair and regeneration. In our study, we verify
in vitro the UC-MSC ability to execute an endochondral
program similar to BM-MSCs and we applied the same
conditions previously described by Scotti et al. [61]. We
seeded UC-MSCs onto the previously mentioned commer-
cial bone substitutes, and we cultured the cell-seeded
constructs in chondrogenic conditions and subsequently in
the hypertrophic medium. We obtained encouraging results
in terms of matrix synthesis and expression of osteogenic
markers (Cbfa1). This certainly represents one of the most
original features of our study. Moreover, our work represents
one of the ﬁrst studies describing the use of UC-MSCs in a
“developmental engineering” paradigm. Indeed, the positive
results observed by “pushing” UC-MSCs through endochon-
dral ossiﬁcation may be exploited by future experiments
verifying the attitude of these cells to generate a tissue similar
to cancellous bone after in vivo preclinical implantation in
small animals, in order to oﬀer a valid use of allogeneic
cell-seeded bone substitutes.
The main limitation of this study is the in vitro nature of
the experiment. This certainly claims for further studies to
verify the intuitions derived from the obtained data in
preclinical animal models before moving to any clinical
applications. Albeit this drawback is implied in any in vitro
study, the preclinical model is essential when dealing with
allogeneic cells to assess the immune privilege of this
category of stem cells before any in vivo human use. How-
ever, literature oﬀers several evidences of UC-MSC immuno-
privileged status. These cells express HLA-G, which is
involved in immune tolerance during pregnancy IL-6 and
VEGF, which are linked to MSC immunosuppressive capa-
bility. Moreover, UC-MSCs are able to suppress T-cell
proliferation [14]. All these aspects seem to conﬁrm the
potential for an allogeneic use of UC-MSC in orthopaedic
tissue engineering.
Nevertheless, a critical issue when dealing with allogeneic
MSCs remains the potential for immune reaction to be
elicited in the host tissue. Evidences in literature are present
outlining the immunogenicity of MSCs from an allogeneic
source and the fact that this reaction may hamper dramati-
cally the tissue regeneration process in the same cells were
supposed to be enhanced. The study of Eliopoulos et al. in
2005 [62] showed the alarming reject of allogeneic MSCs
implanted subcutaneously in mice. A similar fate of these
cells has been observed by Huang et al. [63] in a preclinical
rat model of myocardial infarction. In their study, the
authors showed that allogeneic cells were rejected from the
host cardiac tissues by 5 weeks after implantation. This may
be partially explained by a transient immunoprivileged status
of MSCs that may later acquire immunogenicity during their
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diﬀerentiation and trophic process in the host environment,
thus eliciting an immune reaction by the native immune sys-
tem. Immune reactions and short engraftment time have also
been described by Tano et al. [64] in a model of allogeneic
MSC transplantation on the epicardial surface of rat hearts.
A similar paradigm has been conﬁrmed recently by Oliveira
et al. [65] in a preclinical model of MSC transplantation in
the murine kidney. They observed lymphocytic inﬁltration
and allogeneic MSC rejection no later than 28 days after
transplantation. As a consequence, they suggested the fasci-
nating concept of “preactivation” of cells, by treatment with
INF-gamma and TNF-alpha, in order to reduce immunoge-
nicity and prolong their engraftment period and their trophic
properties. A potential immune reaction in human has been
recently hypothesized by de Windt et al. [31] in their clinical
trial of cartilage repair by means of allogeneic MSCs and
chondrons. Despite their encouraging results, no allogeneic
cells were found at the repair site at 1 year, suggesting a
time-limited trophic eﬀect of MSCs that would have been
gradually removed by the host immune system during
their diﬀerentiation processes. This agrees with a previous
in vitro observations of Mukonoweshuro et al. [66], who
have outlined the immunosuppressive properties but not
the immunoprivileged status of allogeneic chondrogenic-
committed MSCs in a mouse model. The potential immune
reaction elicited by MSCs may also lead to detrimental eﬀect
in the repair setting, as shown preclinically by Sbano et al.
[67] in a mouse model of skin graft transplantation and by
Seifert et al. [68] in a rat kidney transplantation setting.
Overall, these evidences claim for a cautious approach in a
potential clinical application of allogeneic MSCs, despite
the recent literature is outlining, as a counterpart, the safety
and some promising results. Indeed, the studies of Garcia-
Sancho et al. [69] showed a possible application in knee
osteoarthritis and degenerative disc disease with few safety
concerns, probably due to the peculiar “insulated” recipient
site of the cells, and Wang et al. [70] have recently proposed
the injection of allogeneic MSCs during ACl reconstruction
to improve symptoms and structural outcome. With a longer
follow-up, Park et al. [71] have shown the promising eﬀect of
the implantation of a composite made by allogeneic UC
blood-derived MSCs and hyaluronate hydrogel to improve
cartilage healing in osteoarthritic patients. Similar evidences
have been proposed by Vega et al. [72] and by Gupta et al.
[73], who treated knee osteoarthritic patients by a direct
intra-articular injection of allogeneic human MSCs. In a
diﬀerent setting, Morrison et al. [74] have recently demon-
strated the feasibility of cranial bone reconstruction by
means of allogeneic mesenchymal stromal cells (MSCs) on
a ceramic carrier and polymer scaﬀold, similarly to the
preclinical observations of Todeschi et al. [75] regarding
UC-MSC transplantation in mice calvarial defects. So far,
the controversy of allogeneic MSC therapy is still a debated
issue in literature. However, a common element seems to
be present in all these studies. Indeed, a diﬀerent role of
MSCs is emerging from the preclinical and clinical recent evi-
dences that may lead to reconsider the use of allogeneic
MSCs as “replenishing cells for injured tissues,” assuming
their immune system recognition. Far from being a “building
block” submitted to the host immune system (and, thus, with
a limited viability of 2–4 weeks), the allogeneic MSCs may
otherwise represent the transient paracrine catalyzers that
work well for a short period of time with a “hit and run eﬀect”
[65]. This new paradigm implies the lack of the “need of
persistence” in the host tissue, as the therapeutic eﬀects of
MSCs are independent of a direct diﬀerentiation, but they
can be exerted locally by promoting the resident population
to hasten the repair process for a limited period of time, until
the allogeneic MSCs are cleared by the host immune system.
In this perspective, it can be easily understood the greater
eﬀect of implanting allogeneic MSCs in a “conﬁned environ-
ment” (i.e., in the joint or embedded in a bioscaﬀold); as in
these settings, the immune system may be hampered in
rapidly eliminating the MSCs. Furthermore, the various
regenerative properties of allogeneic MSCs observed in
literature may coexist with a reduced survival time due
to the fact that they depend on the factors secreted by
the cells in the ﬁrst days after transplantation, also known
as the “secretome.” Indeed, together with the concept of
MSC preactivation to prolong the cell survival time, the
secretome surely represents one of the future frontiers in
allogeneic MSC tissue engineering research.
In conclusion, the present study conﬁrms the chondro-
genic and osteogenic commitment of UC-MSCs when cul-
tured in tridimensional scaﬀold and it suggests the possible
involvement of UC-MSCs for the generation of endochon-
dral scaﬀolds to improve bone regeneration by recapitulating
endochondral ossiﬁcation process. These observations oﬀer a
solid perspective for future preclinical studies aiming to
improve cartilage repair and bone regeneration. Further-
more, UC-MSCs derive from a previously discarded material
as the umbilical cord; thus, they represent a stem cell popula-
tion with several advantages as a greater bioavailability and
lower ethical implications than other cell sources. All in all,
UC-MSCs may be reasonably considered an attractive
opportunity for orthopaedic allogeneic stem cell therapy.
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